ESMO (European Society for Medical Oncology) Congress 2020
- Start Date:
14 Sep 2020
- End Date:
29 Sep 2020
- Location:
Virtual Conference
POSTER PRESENTATIONS
1
Poster #1322P REAL-WORLD TREATMENT PATTERNS AND IMMUNOTHERAPY (IO) SEQUENCING BASED ON PD-L1 TPS IN EUROPEAN PATIENTS WITH METASTATIC NSCLC
Speakers: Janowicz E, Ognar RG, Capart P, Stoyanov N, Nguyen B, Combest A, Anderson DJC
Date: Thursday, September 17, 2020
2
Poster #1340P REAL-WORLD TREATMENT PATTERNS AND OUTCOMES IN PATIENTS WITH ADVANCED, ALK + NON-SMALL CELL LUNG CANCER (NSCLC) IN EUROPE
Speakers: Stoyanov N, Combest A, Nguyen B, Ognar R, Reitsma D, Capart P, Anderson DJC
Date: Thursday, September 17, 2020
3
Poster #627P REAL-WORLD EVIDENCE (RWE) FOR PATIENTS (PTS) WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) TREATED WITH CABAZITAXEL (CBZ): COMPARISON WITH THE RANDOMIZED CLINICAL STUDY CARD
Speakers: de Wit R, Feedland S, Oudard S, Marinov G, Capart P, Combest A, Peterson R, Ozatilgan A, Morgans A
Date: Thursday, September 17, 2020
PPD WEBINAR
Advancing Early Stage Oncology Research with Adaptive Designs and Master Protocols
Date: Tuesday, September 29, 2020 | 10:00 am EDT
Speakers:
- Jurgen Hummel, MSc, Senior Director of Statistical Science, Biostatistics, PPD
- Dirk Reitsma, MD, Vice President and Therapeutic Area Head, Oncology, Global Product Development, PPD
To be discussed:
- Improved determination of the maximum tolerated dose, comparing different designs for dose selection
- Advantages of basket trial design for finding the most appropriate indication(s)
- Current regulatory positions and outlook of the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human use (ICH)
- Operational implications of different designs